FACTOR XIa INHIBITORS
Selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein, as represented by Formula I, address the inadequacies in managing thrombosis and inflammation by effectively targeting these key enzymes, offering improved treatment options for thrombosis and embolism.
Patent Information
- Application Number
- PCT/US2015/026774
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-04-22
- Filing Date
- 2015-04-21
- Publication Date
- 2015-10-29
AI Technical Summary
Current treatments for thrombosis, embolism, and hypercoagulability lack effective inhibitors for Factor XIa and plasma kallikrein, which are key players in blood coagulation and inflammation, leading to inadequate management of conditions like thromboembolic disorders and diabetic macular edema.
Development of selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein compounds, specifically represented by Formula I, which can be used alone or in combination with other therapeutic agents to treat thrombosis, embolism, and fibrotic changes.
The compounds effectively inhibit Factor XIa and plasma kallikrein, providing therapeutic benefits in conditions such as thrombosis, embolism, and inflammatory disorders, including diabetic macular edema, by reducing thrombogenicity and improving vascular permeability.